Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Alternatives to Laboratory Animals : ATLA|April 16, 2013
Five plus three: legislating for the Five Freedoms and the Three Rs--Animal Welfare Act 1999 (New Zealand)Neil Wells, Judith NicholsonJournal of Proteome Research|October 9, 2012
An iTRAQ proteomics screen reveals the effects of the MDM2 binding ligand Nutlin-3 on cellular proteostasisJudith Nicholson, Kalainanghi Neelagandan, Anne-Sophie Huart, et al.Current Cancer Drug Targets|February 13, 2019
An Integrative "Omics" Approach, for Identification of Bona Fides PLK1 Associated Biomarker in Esophageal AdenocarcinomaNousheen Bibi, Sajid Rashid, Judith Nicholson, et al.Proteomics. Clinical Applications|October 3, 2012
Quantitative mass spectrometry for colorectal cancer proteomicsJuan Martínez-Aguilar, Jenny Chik, Judith Nicholson, et al.British Journal of Cancer|June 23, 2017
No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapyAlexandra K Walker, Christiana Kartsonaki, Elena Collantes, et al.British Journal of Cancer|January 12, 2018
No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapyAlexandra K Walker, Christiana Kartsonaki, Elena Collantes, et al.Cell Cycle (Georgetown, Tex.)|December 31, 2010
Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulationShubhra Ghosh Dastidar, Devanathan Raghunathan, Judith Nicholson, et al.Proteomics|June 9, 2016
Rearrangement of mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide dehydrogenase protein-protein interactions by the MDM2 ligand nutlin-3Luke Way, Jakub Faktor, Petra Dvorakova, et al.Frontiers in Molecular Biosciences|July 29, 2015
The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitorsEleanor R Dickinson, Ewa Jurneczko, Judith Nicholson, et al.Pageof 2